monoclonal antibodies (mAbs)

Orion and Abzena Announce Exclusive Antibody Commercial License

Abzena, an end-to-end integrated CDMO for complex biologics and bioconjugates, announced that Orion has obtained an exclusive focused commercial license to one of Abzena’s mAbs..

Merck Acquires Chromatography Business from JSR Life Sciences

Merck to acquire the chromatography business of JSR Life Sciences, a leading provider of CDMO services, preclinical and translational clinical research, and bioprocessing solutions.

Syngene Acquires its First US Manufacturing Facility

Syngene, a global contract research, development, and manufacturing organization (CRDMO), recently announced the acquisition of its first biologics site in the USA – fitted with multiple monoclonal antibody (mAbs) manufacturing lines.

Biogen Acquires Human Immunology Biosciences

Biogen and Human Immunology Biosciences (HI-Bio), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases (IMDs), have entered into a definitive agreement. Biogen has agreed to acquire HI-Bio for $1.15 billion (€1.06 billion) upfront and up to $650 million (€600.5 million) in potential milestone payments.

Aragen Launches First Phase of Biologics Facility in India

Aragen, a CRDMO, has launched the first phase of its biologics manufacturing facility in Bangalore, India. The $30 million project, executed by its subsidiary Aragen Biologics Pvt Ltd, has completed its first small-scale manufacturing project for a US-based organization, producing a novel anticancer monoclonal antibody.

Novasep and GTP Technology in Monoclonal Antibodies Link

Sanofi in Biologics Collaboration With Boehringer